Financial Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026 byTim AllenOctober 15, 2026
Extremities Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth byJosh SandbergMay 7, 2026
Financial Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 byTim AllenMarch 10, 2026
Biologics Extremities Top Stories Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion byWill SandbergDecember 2, 2025
Biologics Spine Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 byWill SandbergOctober 3, 2025
Biologics Spine Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance byJosh SandbergAugust 5, 2025
Biologics Extremities Spine Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich byTim AllenMay 13, 2025
Financial Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 byTim AllenApril 15, 2025
Biologics Spine Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division byJosh SandbergJanuary 7, 2025
Biologics Extremities Top Stories Kuros Biosciences Expands into Extremities Markets byTim AllenNovember 19, 2024
